|
Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT. |
|
|
|
Consulting or Advisory Role - Daiichi Sankyo; Deciphera; Five Prime Therapeutics; Lilly; Loxo |
Research Funding - AADi (Inst); Daiichi Sankyo (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst) |
|
|
Consulting or Advisory Role - Daiichi Sankyo |
Research Funding - Novartis |
Patents, Royalties, Other Intellectual Property - Author Royalties from Uptodate |
Travel, Accommodations, Expenses - Daiichi Sankyo |
|
|
Employment - Limbguard (I) |
Leadership - Limbguard (I) |
Stock and Other Ownership Interests - Limbguard (I) |
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Ignyta; Lilly; Loxo; NanoCarrier |
Research Funding - AADi (Inst); Arog (Inst); Bayer (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); NanoCarrier (Inst); Plexxikon (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst) |
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I) |
Travel, Accommodations, Expenses - Daiichi Sankyo; Ignyta; NanoCarrier |
|
|
Consulting or Advisory Role - Daiichi Sankyo; Foundation Medicine |
|
|
|
Consulting or Advisory Role - Adaptimmune; Bayer; Caris Life Sciences; CytRx Corporation; Daiichi Sankyo; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Johnson & Johnson; Lilly/ImClone; Novartis; Pfizer; Plexxikon; Threshold Pharmaceuticals |
Speakers' Bureau - Adaptimmune; Caris Life Sciences; GlaxoSmithKline; Johnson & Johnson; Lilly; Novartis |
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma |
Patents, Royalties, Other Intellectual Property - Patent on ALEXT3102; Patent on the use of ME1 as a biomarker |
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Lilly |
|
|
Consulting or Advisory Role - Immune Design |
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); Epizyme (Inst); Lilly (Inst); MabVax (Inst); Morphotek (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); SpringWorks Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - Wolters Kluwer |
Travel, Accommodations, Expenses - SpringWorks Therapeutics |
|
|
Consulting or Advisory Role - Blueprint Medicines; Daiichi Sankyo; Regeneron |
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); CBA Research (Inst); Exelixis (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Philogen (Inst) |
|
|
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Genentech/Roche; Novartis |
Research Funding - AADi; Genentech/Roche; Revolution Medicines |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AADi |
|
|
|
Stock and Other Ownership Interests - AADi |
|
|
|
Stock and Other Ownership Interests - AADi |
|
|
|
|
|
|
|
Stock and Other Ownership Interests - AADi |
|
|
Consulting or Advisory Role - Celgene |
Research Funding - AADi (Inst); Lilly (Inst) |